The System is Extractive.
Traditional clinical trials are too slow and narrowly focused. Consumer wearables lack clinical rigor. We are building the missing bridge.
The Data Quality Paradigm Shift
Pharmaceutical companies spend billions attempting to monitor Phase IV post-market outcomes and pre-clinical signals, often relying on messy, incomplete insurance claims or subjective physician reports. Meanwhile, the world's most engaged demographic—bio-optimizers—are meticulously tracking these exact interventions (peptides, longevity stacks) daily. LifePrint provides the infrastructure to formalize this existing behavior into enterprise-grade Real-World Evidence.
Utility-First Acquisition
The consumer engine is a working protocol-validation tool that bio-optimizers want to use even with no monetization story attached. Acquisition flows through Reddit, Discord, and bio-optimization communities at well below the $40–$2,500 industry-average CAC for D2C health (Brighter Click, 2026). Internal target: <$25 blended through community channels in our first cohort.
The Diagnostic Lock-In
The primary hurdle to longitudinal tracking is churn. By converting anonymized data sales into subsidized diagnostic rewards — funded biomarker panels worth $1,400–$3,000 over a 12-month progression — we transition the user from software consumer to funded research participant, structurally lowering churn versus the 5–7% annual best-in-class healthtech benchmark (Vitally, 2025).
Consent Infrastructure as Moat
Every cohort delivery carries a Data Use Agreement, a cryptographic consent audit trail, and an Expert Determination de-identification review. Pharma buyers pay a premium for data they can defend in an FDA submission — that infrastructure compounds with every cohort and is the regulatory barrier new entrants must rebuild from scratch.